InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd. is an Israeli-based, vertically integrated cannabis company focused on the cultivation, manufacturing, research and distribution of medical cannabis products. Operating under licenses issued by the Israeli Ministry of Health, the company pursues a full value-chain approach from seed to shelf. InterCure’s activities encompass indoor and greenhouse cultivation, cannabinoid extraction, formulation of oils and tinctures, and compliance-driven packaging for both domestic and export markets.

The company’s portfolio is anchored by its controlled subsidiaries, including CannaKids, which develops pediatric-focused cannabis therapies, and Eybna Technologies, a research-driven unit specializing in terpene science. InterCure’s flagship cultivation facility near Ramla features automated climate controls and advanced irrigation systems designed to optimize cannabinoid and terpene profiles. Through partnerships with academic institutions and clinical centers, the company conducts ongoing trials targeting conditions such as chronic pain, neurological disorders and oncology-related symptoms.

InterCure serves patients and healthcare providers across Israel, and has established distribution channels in select European markets. Strategic alliances with licensed distributors in Germany, Italy and other jurisdictions enable the company to navigate complex regulatory frameworks while delivering standardized, GMP-compliant products. Looking ahead, InterCure is exploring opportunities in Latin America and pursuing additional export approvals in Asia-Pacific regions.

Founded in 2015 by industry entrepreneur Ido Kimchi, InterCure leverages a management team with deep expertise in agritech, pharmaceuticals and life-sciences research. The board includes seasoned executives in regulatory affairs, finance and international business development, underscoring the company’s commitment to rigorous quality controls and scalable operations. With a pipeline of next-generation formulations and a growing global footprint, InterCure aims to advance medical cannabis accessibility through science-driven innovation and strategic market expansion.

Key Stats

• Today's Range: $1.48 to $1.53
• 50-Day Range: $1.45 to $1.60
• 52-Week Range: $1.17 to $2.62
• Volume: 76,959 shs
• Average Volume: 25,971 shs
• Market Capitalization: $68.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INCR Stock Analysis - Frequently Asked Questions

How have INCR shares performed this year?

InterCure's stock was trading at $1.59 on January 1st, 2025. Since then, INCR shares have decreased by 5.7% and is now trading at $1.50.

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InterCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV).

Company Calendar

• Today: 7/07/2025
• Next Earnings (Estimated): 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 350
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 1.73
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $238.85 million
• Price / Sales: 0.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 45,573,000
• Free Float: N/A
• Market Cap: $68.36 million
• Optionable: Optionable
• Beta: 1.18